Alfavision Overseas (India) Limited (ALFAVIO.BO)
INR 12.51
(-0.56%)
INR 12.51
(-0.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.76 Million INR | 112.77% |
| 2022 | -21.64 Million INR | -207.58% |
| 2021 | 20.12 Million INR | 35.29% |
| 2020 | 14.87 Million INR | 1639.28% |
| 2019 | 855.12 Thousand INR | -16.31% |
| 2018 | 1.02 Million INR | -52.59% |
| 2017 | 2.15 Million INR | -22.42% |
| 2016 | 2.77 Million INR | 5.87% |
| 2015 | 2.62 Million INR | -2.23% |
| 2014 | 2.68 Million INR | 4.68% |
| 2013 | 2.56 Million INR | 21.08% |
| 2012 | 2.11 Million INR | 202.47% |
| 2011 | 700.09 Thousand INR | -15.14% |
| 2010 | 825 Thousand INR | -30.2% |
| 2009 | 1.18 Million INR | -65.61% |
| 2008 | 3.43 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 865 Thousand INR | -15.28% |
| 2023 Q4 | 1.02 Million INR | 117.43% |
| 2023 Q3 | -5.85 Million INR | -6536.26% |
| 2023 Q2 | 91 Thousand INR | -98.75% |
| 2023 Q1 | 7.3 Million INR | 121.79% |
| 2023 FY | 2.76 Million INR | 112.77% |
| 2022 Q2 | 8.16 Million INR | 155.3% |
| 2022 Q3 | -4.99 Million INR | -161.23% |
| 2022 Q4 | -33.52 Million INR | -570.75% |
| 2022 Q1 | 3.19 Million INR | -72.0% |
| 2022 FY | -21.64 Million INR | -207.58% |
| 2021 Q4 | 11.41 Million INR | 181.21% |
| 2021 Q1 | 262 Thousand INR | -97.27% |
| 2021 Q3 | 4.06 Million INR | -7.35% |
| 2021 Q2 | 4.38 Million INR | 1572.52% |
| 2021 FY | 20.12 Million INR | 35.29% |
| 2020 Q2 | 201 Thousand INR | 29.68% |
| 2020 FY | 14.87 Million INR | 1639.28% |
| 2020 Q1 | 155 Thousand INR | 119.87% |
| 2020 Q3 | 3.69 Million INR | 1736.32% |
| 2020 Q4 | 9.61 Million INR | 160.47% |
| 2019 FY | 855.12 Thousand INR | -16.31% |
| 2019 Q1 | 796 Thousand INR | -93.02% |
| 2019 Q2 | 844 Thousand INR | 6.03% |
| 2019 Q3 | 543 Thousand INR | -35.66% |
| 2019 Q4 | -779.87 Thousand INR | -243.62% |
| 2018 Q1 | -1.86 Million INR | 40.72% |
| 2018 FY | 1.02 Million INR | -52.59% |
| 2018 Q4 | 11.4 Million INR | 248.1% |
| 2018 Q3 | -7.69 Million INR | -281.47% |
| 2018 Q2 | 4.24 Million INR | 327.45% |
| 2017 Q2 | 1.77 Million INR | 1420.51% |
| 2017 FY | 2.15 Million INR | -22.42% |
| 2017 Q1 | 117 Thousand INR | -96.96% |
| 2017 Q3 | 2.42 Million INR | 36.31% |
| 2017 Q4 | -3.14 Million INR | -229.73% |
| 2016 Q4 | 3.84 Million INR | 223.89% |
| 2016 Q3 | -3.1 Million INR | -1511.82% |
| 2016 FY | 2.77 Million INR | 5.87% |
| 2016 Q1 | 1.07 Million INR | 2289.8% |
| 2016 Q2 | 220 Thousand INR | -79.5% |
| 2015 Q4 | -49 Thousand INR | -109.82% |
| 2015 FY | 2.62 Million INR | -2.23% |
| 2015 Q3 | 499 Thousand INR | 12.39% |
| 2015 Q2 | 444 Thousand INR | -68.38% |
| 2015 Q1 | 1.4 Million INR | -18.65% |
| 2014 Q3 | 238 Thousand INR | 17.82% |
| 2014 FY | 2.68 Million INR | 4.68% |
| 2014 Q1 | 1.82 Million INR | 293.05% |
| 2014 Q2 | 202 Thousand INR | -88.95% |
| 2014 Q4 | 1.72 Million INR | 625.2% |
| 2013 Q4 | -946.92 Thousand INR | -414.59% |
| 2013 FY | 2.56 Million INR | 21.08% |
| 2013 Q1 | 678 Thousand INR | -44.5% |
| 2013 Q2 | 1.99 Million INR | 193.81% |
| 2013 Q3 | 301 Thousand INR | -84.89% |
| 2012 Q1 | 380 Thousand INR | 185.71% |
| 2012 Q2 | 174 Thousand INR | -54.21% |
| 2012 FY | 2.11 Million INR | 202.47% |
| 2012 Q3 | 553 Thousand INR | 217.82% |
| 2012 Q4 | 1.22 Million INR | 120.91% |
| 2011 FY | 700.09 Thousand INR | -15.14% |
| 2011 Q3 | 286 Thousand INR | 0.0% |
| 2011 Q4 | 133 Thousand INR | -53.5% |
| 2010 FY | 825 Thousand INR | -30.2% |
| 2010 Q4 | 423 Thousand INR | 0.0% |
| 2009 Q4 | 167 Thousand INR | 0.0% |
| 2009 FY | 1.18 Million INR | -65.61% |
| 2008 FY | 3.43 Million INR | 0.0% |
| 2008 Q4 | 177 Thousand INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biocon Limited | 10.22 Billion INR | 99.973% |
| Blue Jet Healthcare Limited | 1.63 Billion INR | 99.831% |
| Concord Biotech Limited | 3.08 Billion INR | 99.91% |
| Dishman Carbogen Amcis Limited | -1.53 Billion INR | 100.18% |
| FERMENTA BIOTECH LIMITED | -230.59 Million INR | 101.199% |
| GENOMIC VALLEY BIOTECH LIMITED | 151.81 Thousand INR | -1720.601% |
| Lyka Labs Limited | -24.89 Million INR | 111.103% |
| Panacea Biotec Limited | -11.73 Million INR | 123.564% |
| SAMSRITA LABS LIMITED | -2.62 Million INR | 205.398% |
| Servoteach Industries Limited | -2.37 Million INR | 216.428% |
| SMS Lifesciences India Limited | 90.92 Million INR | 96.96% |
| Supriya Lifescience Limited | 1.19 Billion INR | 99.768% |
| Syngene International Limited | 5.1 Billion INR | 99.946% |
| TAKE Solutions Limited | -1.19 Billion INR | 100.231% |
| Titan Biotech Limited | 248.53 Million INR | 98.888% |
| Transgene Biotek Limited | -6.55 Million INR | 142.166% |
| Vanta Bioscience Limited | -23.15 Million INR | 111.935% |